Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
ADNOC Gas Targets Up to $4B Profit in 2026 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
WuXi AppTec Co., a leading drug development and manufacturing services provider, saw its shares climb sharply on Tuesday following the release of strong first-quarter earnings. The company, listed in both Hong Kong and Shanghai, reported impressive financial growth driven by rising demand across its core Contract Research, Development, and Manufacturing Organization (CRDMO) business.
For the January to March period, WuXi AppTec posted revenue of 12.44 billion yuan (approximately $1.7 billion), marking a 28.8% year-on-year increase. Net profit attributable to shareholders also grew significantly, rising 26.7% to 4.65 billion yuan. This solid performance boosted investor confidence, sending its Hong Kong-listed shares up by 15% to HK$144.8, the highest level recorded since December 2021.
The company’s strong quarterly results were largely fueled by exceptional growth in its chemistry segment, where revenue surged by 43.7%. This growth was supported by expanded capabilities in small-molecule development and manufacturing services, a key area within the global pharmaceutical outsourcing market. Increased operational efficiency and higher capacity utilization also contributed to improved profitability, highlighting WuXi AppTec’s ability to scale effectively amid growing demand.
In addition to chemistry services, the company reported steady gains in other business segments. Revenue from its testing division rose 27.4%, while the biology segment recorded a 10.1% increase. These gains reflect continued customer demand and the company’s strategic focus on emerging drug modalities, including nucleic acids and peptide-based therapies.
WuXi AppTec’s strong earnings performance underscores its position as a major player in the global biotech and pharmaceutical services industry. With ongoing expansion and rising demand for outsourced drug development solutions, the company remains well-positioned for sustained growth, making it a key stock to watch in the healthcare and life sciences sector.
